GLP-1 drugs commonly used for weight loss and diabetes decreased the risk of cancer spreading in patients with several ...

By HealthDay Staff HealthDay ReporterWEDNESDAY, May 27, 2026 (HealthDay News) — A new study suggests GLP-1 medications may ...

A Cleveland Clinic study finds Ozempic-style GLP-1 drugs may significantly slow the spread of several obesity-related cancers ...

GLP-1 medications were initially developed and prescribed to help manage blood sugar in people with Type 2 diabetes ...

A Cleveland Clinic study suggests GLP-1 weight loss drugs may help slow the spread of some obesity-related cancers.

Real-world data show that GLP-1 receptor agonists (GLP-1s) may reduce metastatic progression of certain obesity-related ...

GLP-1 drugs may be linked to a lower risk of cancer progression, according to new research that will be presented next week at the American Society of Clinical Oncology’s annual meeting.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have garnered significant attention recently, both in the media and in doctors’ offices. Originally developed as a treatment for type 2 diabetes, ...

Primary care practitioners serve a critical role in optimizing clinical outcomes for adults with T2DM by evaluating underlying mechanisms, treatment efficacy, medication safety profiles, and ...

Please provide your email address to receive an email when new articles are posted on . No difference in thyroid cancer risk was found for adults with type 2 diabetes using a GLP-1 receptor agonist vs ...

Please provide your email address to receive an email when new articles are posted on . GLP-1 receptor agonists conferred greater HbA1c reductions in older adults than younger adults. Older adults had ...

GLP-1RA and SGLT2 inhibitor combination therapy was associated with better cardiorenal outcomes than monotherapy among patients with type 2 diabetes. The cardiorenal benefits of sodium-glucose ...